Anuradha Acharya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anuradha Acharya has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Sachin Kumar Singh
School of Pharmaceutical Sciences Lovely Professional University Phagwara Punjab India
3 shared publications - Harish Dureja
Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak, India
2 shared publications - Kaustubh Ajit Kolekar
School of Pharmaceutical Sciences Lovely Professional University Phagwara Punjab India
2 shared publications Bushra Bashir
SYBES’s Bombay Institute of Pharmacy and Research Dombivli (East) Maharashtra India
1 shared publication- Bushra Bashir
School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India
1 shared publication Gaurav Gupta
1 shared publication
Latest Publications
- Open Access
- 7 September 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (37) , e71672
Opening Avenues for Rheumatoid Arthritis Treatment via Transdermal Application of Microneedles: Progress so far and Future Outlook
Rheumatoid arthritis (RA) is a chronic autoimmune disease with a global prevalence of 0.5% to 2%, causing serious impairment and early mortality. Presently approved therapeutics comprising non‐steroidal anti‐inflammatory drugs (NSAIDs), disease‐modifying anti‐rheumatic drugs (DMARDs), corticosteroids, etc. only lower pain, edema, and inflammation. Most of these therapeutics have been administered orally, intravenously, and intra‐articularly, minimizing patient adherence. Additionally, high doses of these drugs need to be taken for a long duration and have poor specificity, causing fatal side effects. The conventional and nanocarrier (NCs)‐based topical cargo delivery pose challenges like poor residence, possibility of skin reactions, and low patient adherence. Therefore, transdermal delivery of these therapeutics using microneedles (MNs) can be promising to improve permeability, bioavailability, targeting, and patient compliance while minimizing side effects. Moreover, NCs‐assisted MNs, biomimetic NCs‐based MNs, and MNs for biologics delivery have also emerged as a promising platform for targeting RA efficiently. This review attempts to give an overview on the transdermal drug delivery using MNs and NCs‐based MNs in the efficient management of RA. Thus, different MNs and their amalgamation with NCs could effectively deliver and manage RA via the transdermal route.
- 7 September 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (37) , e71672
Open AccessOpening Avenues for Rheumatoid Arthritis Treatment via Transdermal Application of Microneedles: Progress so far and Future Outlook
Rheumatoid arthritis (RA) is a chronic autoimmune disease with a global prevalence of 0.5% to 2%, causing serious impairment and early mortality. Presently approved therapeutics comprising non‐steroidal anti‐inflammatory drugs (NSAIDs), disease‐modifying anti‐rheumatic drugs (DMARDs), corticosteroids, etc. only lower pain, edema, and inflammation. Most of these therapeutics have been administered orally, intravenously, and intra‐articularly, minimizing patient adherence. Additionally, high doses of these drugs need to be taken for a long duration and have poor specificity, causing fatal side effects. The conventional and nanocarrier (NCs)‐based topical cargo delivery pose challenges like poor residence, possibility of skin reactions, and low patient adherence. Therefore, transdermal delivery of these therapeutics using microneedles (MNs) can be promising to improve permeability, bioavailability, targeting, and patient compliance while minimizing side effects. Moreover, NCs‐assisted MNs, biomimetic NCs‐based MNs, and MNs for biologics delivery have also emerged as a promising platform for targeting RA efficiently. This review attempts to give an overview on the transdermal drug delivery using MNs and NCs‐based MNs in the efficient management of RA. Thus, different MNs and their amalgamation with NCs could effectively deliver and manage RA via the transdermal route.
- Open Access
- 20 January 2025
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 24, 179-180
Combination therapy of mitochondria-targeted antioxidants and polyphenols for early intervention in Huntington’s disease
- 20 January 2025
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 24, 179-180
Open AccessCombination therapy of mitochondria-targeted antioxidants and polyphenols for early intervention in Huntington’s disease